ERBB2 and breast carcinoma: Given the above results with thapsigargin, we tested whether lower levels of CHIP expression in ErbB2-overexpresisng breast cancer cells could indeed sensitize them to acute elevation of ER stress with Bortezomib, a clinically used drug known to induce ER stress [49,53,54] and lead to an anti-tumor effect.